|
PMN
|
It is not the same. ATE has $22M cash in hands and they are officially a PIII...
|
|
PMN
|
It is not the short who kill this company - it is the management team. Each...
|
|
ATBPF
|
$28 is a conditional and discounted present value - conditional on successful...
|
|
ATBPF
|
I don't think ATE needs money any time soon either. We still have $22M in...
|
|
ATBPF
|
ATE is going to finance PIII through issuing common share, preferred share...
|
|
ATBPF
|
This short form base shelf prospectus relates to Antibe Therapeutics Inc.’s (...
|
|
ATBPF
|
If Antibe would be able to fully unload Citagenix, I am also okay with...
|
|
PMN
|
At $500K/month burning rate, $1.8M would not last long. M101 wrote: So out of...
|
|
ATBPF
|
Maybe uplist to Nasdaq ...... Obviously, it is something materail but not...
|
|
PMN
|
Alzheon’s ALZ-801 is an orally administered amyloid oligomer inhibitor + $47M...
|
|
PMN
|
It doesn't matter whether PMN310 is better than BAN2401 or not. The fate...
|
|
PMN
|
Two closings with gross proceeds less than $2M = 4 months life span. And then...
|
|
ATBPF
|
Here's what I found with Google. What are the rules to...
|
|
ATBPF
|
Simply Wall Street is a joke. It tried to use revenue to valuate a...
|
|
PMN
|
Don't forget, Denali Therapeutics has Sanofi and Alector has Abbvie...
|
|
PMN
|
Yes and no. I even don't believe that PMN be able to complete the second...
|
|
PMN
|
Big pharms are scared away by so many failures. PMN could be sold at only...
|
|
PMN
|
Which one doesn't make sense more? The SP, or, the salary get paid to the...
|
|
PMN
|
You smart. There is no hope without scheduled clinical trial. There is no...
|
|
PMN
|
The science is great but the management sucks. And, you expect the management...
|